Applied DNA Sciences Reports Fiscal Second Quarter 2017 Financial Results

May 11, 2017 4:05 PM

Company to Hold Conference Call and Webcast Today at 4:30 PM Eastern Time

STONY BROOK, N.Y.--(BUSINESS WIRE)-- Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA”, or "the Company"), a provider of DNA-based supply chain, anti-counterfeiting and anti-theft technology, product genotyping and DNA mass production for diagnostics, announced financial results for the fiscal 2017 second quarter ended March 31, 2017.

“Our fiscal second quarter was distinguished by the continued development of commercial activity and a high number of pre-commercial opportunities, both of which we believe lay the groundwork for greater commercial-scale adoption of our SigNature® DNA platform,” stated Dr. James A. Hayward, president and CEO of Applied DNA. “Revenue in the quarter was driven primarily by the recognition of deferred cotton revenue and from our synthetic fiber and consumer asset marking markets.”

“We have made strides in diversifying our recurring revenue in fiscal 2017, building upon the base that began in 2013 with the Defense Logistics Agency and has expanded since then with asset and auto tagging in Europe and the long term cotton contracts between Himatsingka and their customer,” continued Dr. Hayward. “Building on the annual revenue commitments in cotton we announced in the first fiscal quarter, in the second fiscal quarter we shipped our fourth purchase order from Techmer to SigNature T tag synthetic fiber and launched our CertainT™ platform, which we believe will create a new revenue stream with the licensing of our CertainT logo to brands and retailers, indicating the use of our tag, test and track platform. Subsequent to the close of the quarter, we entered into a five-year agreement to supply bulk DNA that is expected to generate approximately $500,000 annually and we shipped our fifth purchase order from Techmer. Cumulatively, we believe these milestones evidence the steady maturation of our revenue model and further penetration of our business verticals.”

“Also after the close of the quarter, we announced that Bed, Bath and Beyond debuted its new Wamsutta PimaCott™ home fashion products line, which uses our SigNature T technology. From our perspective, the debut of SigNature T at one of the country’s biggest home textile retailers (Home Textiles Today, 2016 Survey) validates our cotton strategy, elevates the discussion on supply chain security and authenticity and positions our technology platform as the solution through which brands and retailers can mitigate risk and uncertainty in their global supply chains.”

Second Quarter Financial Highlights:

Concluded Dr. Hayward, “Looking ahead to the second half of the fiscal year, we believe we will continue the recognition of deferred revenue from SigNature T marked cotton, supplemented by non cotton derived revenue sources. We are seeing increasing interest in the marking of synthetic fiber for home textile use, including our program with Loftex Home, where synthetics are increasingly used as an alternative to cotton. With the transferability of our technology and our unique competitive position in securing bulk products and commodities, we are experiencing shortened development and sales cycles and a growing pipeline of pre-commercial opportunities. We believe we are well positioned to continue closing commercial-scale contracts and broadening the adoption of our technology platform.”

Six-Month Financial Highlights:

Operational Highlights:

Fiscal 2017 Second Quarter Conference Call Information

The Company will hold a conference call and webcast to discuss its fiscal 2017 second-quarter results on Thursday May 11, 2017 at 4:30 PM EST. To participate on the conference call, please follow the instructions below. While every attempt will be made to answer investors’ questions on the Q&A portion of the call, due to the large number of expected participants, not all questions may be answered.

To Participate:

For Replay (available 1 hour following the conclusion of the live call):

Information about Non-GAAP Financial Measures

As used herein, “GAAP” refers to accounting principles generally accepted in the United States of America. To supplement our condensed consolidated financial statements prepared and presented in accordance with GAAP, this earnings release includes Adjusted EBITDA, which is a non-GAAP financial measure as defined in Rule 101 of Regulation G promulgated by the Securities and Exchange Commission. Generally, a non-GAAP financial measure is a numerical measure of a company’s historical or future performance, financial position, or cash flows that either excludes or includes amounts that are not normally excluded or included in the most directly comparable measure calculated and presented in accordance with GAAP. The presentation of this non-GAAP financial information is not intended to be considered in isolation or as a substitute for, or superior to, the financial information prepared and presented in accordance with GAAP. We use this non-GAAP financial measure for internal financial and operational decision making purposes and as a means to evaluate period-to-period comparisons of the performance and results of operations of our core business. Our management believes that these non-GAAP financial measures provide meaningful supplemental information regarding the performance of our business by excluding non-cash expenses that may not be indicative of our recurring operating results. We believe this non-GAAP financial measure is useful to investors as it allows for greater transparency with respect to key metrics used by management in its financial and operational decision making.

“EBITDA”- is defined as earnings (loss) before interest expense, income tax expense and depreciation and amortization expense.

“Adjusted EBITDA”- is defined as EBITDA adjusted to exclude (i) stock-based compensation and (ii) other non-cash expenses.

About Applied DNA Sciences

Applied DNA Sciences makes life real and safe by providing innovative, molecular-based technology solutions and services that can help protect products, brands, entire supply chains, and intellectual property of companies, governments and consumers from theft, counterfeiting, fraud and diversion. The proprietary DNA-based “CertainT™” Platform can be used to identify, tag, track, and trace products, to help assure authenticity, origin, traceability and quality of products. SigNature® DNA describes the core technology ingredient that is at the heart of a family of uncopyable, security and authentication solutions such as SigNature® T and fiberTyping®, targeted toward textiles and apparel, BackTrac™ and DNAnet®, for anti-theft and loss prevention, and digitalDNA®, providing powerful track- and-trace. All provide a forensic chain of evidence, and can be used to prosecute perpetrators. Applied DNA Sciences is also engaged in the large-scale production of specific DNA sequences using the polymerase chain reaction.

Go to adnas.com for more information, events and to learn more about how Applied DNA Sciences makes life real and safe. Common stock listed on NASDAQ under the symbol APDN, and warrants are listed under the symbol APDNW.

Forward-Looking Statements

The statements made by APDN in this press release may be “forward-looking” in nature within the meaning of the Private Securities Litigation Act of 1995. Forward-looking statements describe APDN’s future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of APDN. Actual results could differ materially from those projected due to our short operating history, limited financial resources, limited market acceptance, market competition and various other factors detailed from time to time in APDN’s SEC reports and filings, including our Annual Report on Form 10-K filed on December 6, 2016, and our quarterly reports on Form 10-Q filed on February 9, 2017 and May 11, 2017, which are or will be available at www.sec.gov. APDN undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof to reflect the occurrence of unanticipated events, unless otherwise required by law.

Financial Tables Follow

APPLIED DNA SCIENCES, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

March 31, September 30,
2017 2016
ASSETS (unaudited)
Current assets:
Cash and cash equivalents $ 4,020,412 $ 4,479,274

Accounts receivable, net of allowance of $29,902 and $32,965 at March 31, 2017 andSeptember 30, 2016, respectively

5,192,358 6,374,895
Inventories 353,582 297,759
Prepaid expenses and other current assets 182,848 200,006
Total current assets 9,749,200 11,351,934

Property, plant and equipment-net of accumulated depreciation of $1,464,845 and $1,263,200 atMarch 31, 2017 and September 30, 2016, respectively

672,347 792,499
Other assets:
Long term accounts receivables 1,044,780 1,535,000
Deposits 61,626 61,126
Deferred offering costs - 13,986
Goodwill 285,386 285,386

Intangible assets, net of accumulated amortization of $545,915 and $423,649, as ofMarch 31,2017 and September 30, 2016, respectively

1,403,634 1,525,900
Total Assets $ 13,216,973 $ 15,565,831
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable and accrued liabilities $ 1,896,154 $ 2,247,341
Deferred revenue 1,325,140 1,837,588
Total current liabilities 3,221,294 4,084,929

Long term accounts payable

141,099 215,500
Long term deferred revenue 563,634 900,000

Total liabilities 3,926,027 5,200,429
Commitments and contingencies
Stockholders’ Equity

Preferred stock, par value $0.001 per share; 10,000,000 shares authorized; -0- shares issued andoutstanding as of March 31, 2017 and September 30, 2016

- -

Series A Preferred stock, par value $0.001 per share; 10,000,000 shares authorized; -0- issued andoutstanding as of as of March 31, 2017 and September 30, 2016

- -

Series B Preferred stock, par value $0.001 per share; 10,000,000 shares authorized; -0- issued andoutstanding as of March 31, 2017 and September 30, 2016

- -

Common stock, par value $0.001 per share; 500,000,000 shares authorized; 26,351,483 and24,078,756 shares issued and outstanding as of March 31, 2017 and September 30, 2016,respectively

26,351 24,079
Additional paid in capital 240,472,224 234,158,711
Accumulated deficit (231,207,629) (223,817,388)
Total stockholders’ equity 9,290,946 10,365,402
Total Liabilities and Stockholders’ Equity $ 13,216,973 $ 15,565,831

APPLIED DNA SCIENCES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

Three Months Ended March 31, Six Months Ended March 31,
2017 2016 2017 2016
Revenues:
Product revenues $ 689,188 $ 178,371 $ 1,393,605 $ 871,585
Service revenues 216,185 394,951 414,776 1,025,851
Total revenues 905,373 573,322 1,808,381 1,897,436
Cost of revenues 297,372 253,734 572,204 514,646
Operating expenses:
Selling, general and administrative 3,230,371 2,522,735 7,131,288 5,619,051
Research and development 635,893 1,073,079 1,154,521 1,742,147
Depreciation and amortization 163,368 170,981 325,345 389,327
Total operating expenses 4,029,632 3,766,795 8,611,154 7,750,525
LOSS FROM OPERATIONS (3,421,631 ) (3,447,207 ) (7,374,977 ) (6,367,735 )
Other income (expense):
Interest income, net 1,204 4,062 2,535 6,907
Other expense, net (8,429 ) (24,478) (17,798 ) (33,065)
Net loss before provision for income taxes (3,428,856 ) (3,467,623 ) (7,390,240 ) (6,393,893 )
Provision for income taxes
NET LOSS $ (3,428,856 ) $ (3,467,623 ) $ (7,390,240 ) $ (6,393,893 )
Net loss per share-basic and diluted $ (0.13 ) $ (0.14 ) $ (0.29 ) $ (0.27 )
Weighted average shares outstanding-
Basic and diluted 26,351,483 24,072,092 25,886,892 23,307,134

APPLIED DNA SCIENCES, INC.

CALCULATION AND RECONCILIATION OF ADJUSTED EBITDA

(Unaudited)

Three Months Ended March 31, Six Months Ended March 31,
2017 2016 2017 2016
Net Loss $ (3,428,856 ) $ (3,467,623 ) $ (7,390,240 ) $ (6,393,893 )
Interest (income) expense, net (1,204 ) (4,062 ) (2,535 ) (6,907 )
Depreciation and amortization 163,368 170,981 325,345 389,327
Stock based compensation expense 537,904 499,668 1,995,924 954,781
Bad debt expense 15,601 10,000 21,247 22,313
Total non-cash items 715,669 676,587 2,339,981 1,359,514
Consolidated Adjusted EBITDA (loss) (2,713,187 ) (2,791,036 ) (5,050,259 ) (5,034,379 )

Applied DNA Sciences, Inc.

Investors:

Debbie Bailey, 631-240-8817

debbie.bailey@adnas.com

or

LHA

Sanjay M. Hurry, 212-838-3777

shurry@lhai.com

or

Media:

Dian Griesel Int’l.

Susan Forman, 212-825-3210

sforman@dgicomm.com

or

web: www.adnas.com

twitter: @APDN

Source: Applied DNA Sciences, Inc.

Categories

Press Releases

Next Articles